Inhibition Of S100A9 Mitigates Aging-Related Mitochondrial Dysfunction And Neurodegeneration In Parkinson’S Disease
Aging is a significant risk factor for Parkinson’s disease, a condition characterized by the progressive loss of brain cells that produce dopamine, a chemical crucial for movement. Recent research has shed light on the role of a specific protein, S100A9, which is known to be involved in various age-related conditions. This protein appears to act as a critical link between the aging process and the degeneration of brain cells seen in Parkinson’s disease.
The study revealed that when S100A9 protein was introduced, it led to changes in brain support cells, called astrocytes, that resembled cellular aging and reduced the activity of genes responsible for creating new mitochondria. Mitochondria are often referred to as the “powerhouses” of our cells, generating the energy they need to function.
Crucially, when S100A9 was blocked, there were notable improvements. Movement difficulties were alleviated, the density of dopamine-producing nerve fibers was restored, and markers of cellular aging decreased. Furthermore, genes associated with healthy mitochondrial function were upregulated, meaning their activity increased.
These findings suggest that targeting S100A9 could be a promising new approach to develop treatments for Parkinson’s disease, potentially by mitigating cellular aging and repairing mitochondrial damage, which are key contributors to the disease’s progression.
Source: link to paper